Home
Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Market Share Analysis for May 2026

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced positive results from a Phase 1 single-ascending-dose (SAD) study of aritinercept (AUR200), its dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL). The study investigated aritinercept doses of 5 mg, 25 mg, 75 mg, 150 mg, 225 mg and 300 mg and placebo, administered by subcutaneous injection, in 61 healthy subjects.

Finance > Investing

Domainauriniapharma.com

Year Founded2013

Employees51 - 200

Annual Revenue$200M - $500M

Aurinia Pharmaceuticals

Aurinia Pharmaceuticals (including company regionals)

auriniapharma.com

See more website traffic and engagement information

Aurinia Pharmaceuticals Revenue up to May 2026 is 200M - 500M

revenue generated by Aurinia Pharmaceuticals top domains

Aurinia Pharmaceuticals top domains revenue over 3 years

Revenue for Aurinia Pharmaceuticals top domains

auriniapharma.com200M - 500M

See more with Sales Intelligence

Total visits to Aurinia Pharmaceuticals's top domains

Understand Aurinia Pharmaceuticals market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

auriniapharma.com4.6K

See more with Sales Intelligence

Avg. visit duration in Aurinia Pharmaceuticals's top domains

Analyze Aurinia Pharmaceuticals engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

auriniapharma.com00:00:14

See more with Sales Intelligence

Avg. pageviews on Aurinia Pharmaceuticals's top domains

See how Aurinia Pharmaceuticals keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

auriniapharma.com1.66

See more with Sales Intelligence

Aurinia Pharmaceuticals top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by Aurinia Pharmaceuticals

These are the website technologies, by industry, used by Aurinia Pharmaceuticals top domains

Payment & Currencies (6)

Euro

Marketing (5)

Google Marketing Platform

Email Services (2)

Microsoft Exchange Online

Mobile (2)

Meta Viewport

More Technologies

13

See all

News & Signals from Aurinia Pharmaceuticals

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsAurinia Pharmaceuticals Inc. attended event European Alliance of Associations for Rheumatology (EULAR) 2026 Congress on Jun 4th '26.ROCKVILLE, Maryland and EDMONTON, Alberta - June 4, 2026 - Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced that a new analysis of the AURORA 1 Phase 3 study of LUPKYNIS(R) in the treatment of lupus nephritis is being presented at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress (EULAR 2026 Presentation).

NewsAurinia Pharmaceuticals Inc. hired Tang as CEO on Mar 23rd '26.The acquisition of Kezar is coming from autoimmune specialist Aurinia Pharmaceuticals, which named Tang as its new CEO last week.

NewsAurinia Pharmaceuticals Inc. promoted Kevin Tang to principal executive officer on Mar 1st '26.* In March 2026, Aurinia Pharmaceuticals underwent a sweeping leadership overhaul, with Board Chair Kevin Tang becoming CEO and principal executive officer, joined by new CFO Michael Hearne, COO Ryan Cole, and Chief Scientific Officer Thomas Wei as several prior C-suite leaders departed.